312 related articles for article (PubMed ID: 12083326)
1. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Reinis M; Vandasová J; Stanková M; Linka M; Brůcková M
Acta Virol; 2001; 45(5-6):279-86. PubMed ID: 12083326
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort.
Horban A; Stanczak JJ; Bakowska E; Tobolewska EJ; Przybylska-Stengiel KJ; Stanczak GP; Burkacka E
Infection; 2002 Dec; 30(6):356-9. PubMed ID: 12478325
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Liu J; Yue J; Wu S; Yan Y
Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
[TBL] [Abstract][Full Text] [Related]
5. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
[TBL] [Abstract][Full Text] [Related]
6. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of HIV-1 polymerase gene mutations in pre-treated patients in Thailand.
Chantratita W; Jenwitheesuk E; Watitpun C; Pongthanapisith V; Vibhagool A; Leechawengwong M; Sookpranee M; Apairatana A
Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):80-4. PubMed ID: 12118466
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
[TBL] [Abstract][Full Text] [Related]
9. Comparative performance evaluation of the HIV-1 LiPA protease and reverse transcriptase resistance assay on clinical isolates.
Tsongalis GJ; Gleeson T; Rodina M; Anamani D; Ross J; Joanisse I; Tanimoto L; Ziermann R
J Clin Virol; 2005 Dec; 34(4):268-71. PubMed ID: 16286050
[TBL] [Abstract][Full Text] [Related]
10. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors.
Winters MA; Coolley KL; Girard YA; Levee DJ; Hamdan H; Shafer RW; Katzenstein DA; Merigan TC
J Clin Invest; 1998 Nov; 102(10):1769-75. PubMed ID: 9819361
[TBL] [Abstract][Full Text] [Related]
11. Single- and multidrug resistance mutations to reverse transcriptase and protease inhibitors: human immunodeficiency virus type 1-infected patients from two geographical areas in Spain. Spanish Groups for Antiretroviral Resistance Studies.
Pérez-Alvarez L; Villahermosa ML; Cuevas MT; Delgado E; Manjón N; Vázquez de Parga E; Medrano L; Contreras G; Thomson MM; Colomo C; Taboada JA; Nájera R
J Hum Virol; 2000; 3(3):150-6. PubMed ID: 10881995
[TBL] [Abstract][Full Text] [Related]
12. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay.
Sharma PL; Chatis PA; Dogon AL; Mayers DL; McCutchan FE; Page C; Crumpacker CS
Virology; 1996 Sep; 223(2):365-9. PubMed ID: 8806572
[TBL] [Abstract][Full Text] [Related]
13. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.
Flandre P; Descamps D; Joly V; Meiffrédy V; Tamalet C; Izopet J; Aboulker JP; Brun-Vézinet F
Antivir Ther; 2003 Feb; 8(1):65-72. PubMed ID: 12713066
[TBL] [Abstract][Full Text] [Related]
15. Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients.
Fontaine E; Lambert C; Servais J; Ninove D; Plesséria JM; Staub T; Arendt V; Kirpach P; Robert I; Schneider F; Hemmer R; Schmit JC
J Hum Virol; 1998; 1(7):451-6. PubMed ID: 10195266
[TBL] [Abstract][Full Text] [Related]
16. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Marcelin AG; Delaugerre C; Wirden M; Viegas P; Simon A; Katlama C; Calvez V
J Med Virol; 2004 Jan; 72(1):162-5. PubMed ID: 14635026
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors.
Villahermosa ML; Contreras G; Pérez-Alvarez L; Bru F; Medrano L; Delgado E; Colomo C; Thomson M; Nájera R
Antivir Ther; 1998; 3(4):221-7. PubMed ID: 10682142
[TBL] [Abstract][Full Text] [Related]
18. Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues.
Clarke JR; Kaye S; Babiker AG; Hooker MH; Tedder R; Weber JN
J Virol Methods; 2000 Aug; 88(2):117-24. PubMed ID: 10960699
[TBL] [Abstract][Full Text] [Related]
19. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
Masquelier B; Pellegrin I; Ruffault A; Ragnaud JM; Morlat P; Michelet C; Doignon F; Biteau N; Fleury HJ
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):330-4. PubMed ID: 7533640
[TBL] [Abstract][Full Text] [Related]
20. Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.
Marcelin AG; Flandre P; Furco A; Wirden M; Molina JM; Calvez V;
Antivir Ther; 2006; 11(6):693-9. PubMed ID: 17310813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
